Small patient populations, complex administration, high costs of therapies, and government policy interventions are just a few obstacles in rare disease. EVERSANA’s Managing Director, Bill O’Bryon, and Senior Director, Diann Johnson, outline key insights to consider in your launch strategy: Market dynamics impacting rare disease therapies The entire rare community: patients, caregivers, providers & advocates […]
Setting drug prices is a high-stakes endeavor, and that is especially true for the latest round of gene and curative products coming to market in Europe. Drugmakers need to consider several factors that can help them set their product prices appropriately, including the risk of recurrence/relapse, differences in efficacy among cures, and comparators, including full […]
Today’s patients are far more engaged than the previous era of “doctor knows best.” And, like all modern consumers, they expect outcomes to be personalized, delivered on their terms, powered by technology, and of high value. As a result, the next generation of patient services can no longer depend on the “one-size-fits-all” model. Manufacturers can […]
A Conversation with Pharmaceutical Commerce & Jim Lang, Chief Executive Officer, EVERSANA Not quite a year ago, an assemblage of pharma service providers came into being as EVERSANA. Funded by two private equity firms with a background in healthcare—Water Street Healthcare Partners and JLL Partners, there were six acquisitions at the time: Dohmen Life Science […]
In our value-driven healthcare environment, improving the quality of patients’ lives is dependent upon our ability to effectively locate and engage with patients, as well as support the therapeutic onboarding and adherence of patient populations. Delivering best-in-class patient experiences – experiences that positively impact adherence – involves a comprehensive suite of coordinated and intertwined services […]
Each year, Medical Marketing & Media compiles a list of the top 100 medical marketing agencies in North America. As MM&M Editor Stephen Madden shares at the opening of the July issue, “A typical issue of MM&M has 56 pages; with 244, this beast has almost five times as many.” From agencies A to Z, […]
With only three approved products in the marketplace, how do we build a regenerative medicine ecosystem that delivers more value to patient’s faster?
Is your culture patient-centric? It needs to be because today’s patients are motivated information seekers – empowered decision-makers with respect to their treatment. Their voice is key to your success.
EVERSANA attended (and sponsored) The Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting. If you missed the conference, here are a few key takeaways from our colleagues who attended: 1) Federal and State Legislature Update Increases in federal and state policies are putting more pressure on drug prices The possible removal […]
Value propositions need to justify product pricing by focusing on the burden of severe illnesses and how the products address unmet needs.